CLEC12A and breast cancer: This study thereby established that in non-hematopoietic cells, CLEC12A bypassed the canonical TLR-mediated signaling and adopted an alternative pathway of restraining inflammation and promoting cell death in the presence of ART, in both mice mammary tumors and breast CSCs.